Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV)
infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with
Idiopathic Pulmonary Fibrosis